Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: The available treatment option for any type of cancer including CTCL is chemotherapy and radiation therapy which indiscriminately persuade on the normal cells. One way out for selective destruction of CTCL cells without damaging normal cells is the use of histone deacetylase inhibitors (HDACi). Despite promising results in the treatment of CTCL, these HDACi have shown a broadband inhibition profile, moderately selective for one HDAC class but not for a particular isotype. The prevalence of drug-induced side effects leaves open a narrow window of speculation that the decreased therapeutic efficacy and observed side effects may be most likely due to non specific HDAC isoform inhibition. The aim of this paper is to synthesis and evaluates HDAC8 isoform specific inhibitors.
METHODS: Based on the preliminary report on the design and in silico studies of 52 hydroxamic acid derivatives bearing multi-substituent heteroaromatic rings with chiral amine linker, five compounds were shortlisted and synthesized by microwave assisted approach and high yielding synthetic protocol. A series of in vitro assays in addition to HDAC8 inhibitory activity was used to evaluate the synthesised compounds.
RESULTS: Inhibitors 1e, 2e, 3e, 4e and 5e exerted the anti-proliferative activities against CTCL cell lines at 20- 100 µM concentrations. Both the pyrimidine- and pyridine-based probes exhibited μM inhibitory activity against HDAC8. The pyrimidine-based probe 1e displayed remarkable HDAC8 selectivity superior to that of the standard drug, SAHA with an IC50 at 0.1µM.
CONCLUSION: Our study demonstrated that simple modifications at different portions of pharmacophore in the hydroxamic acid analogues are effective for improving both HDAC8 inhibitory activity and isoform selectivity. Potent and highly isoform-selective HDAC8 inhibitors were identified. These findings would be expedient for further development of HDAC8-selective inhibitors.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2019 |
---|---|
Erschienen: |
2019 |
Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
---|---|
Enthalten in: |
Anti-cancer agents in medicinal chemistry - 19(2019), 7 vom: 29., Seite 916-934 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Umamaheswari, Appavoo [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 28.02.2020 Date Revised 28.02.2020 published: Print Citation Status MEDLINE |
---|
doi: |
10.2174/1871520619666190301150254 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM294610235 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM294610235 | ||
003 | DE-627 | ||
005 | 20231225081848.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2019 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2174/1871520619666190301150254 |2 doi | |
028 | 5 | 2 | |a pubmed24n0982.xml |
035 | |a (DE-627)NLM294610235 | ||
035 | |a (NLM)30836926 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Umamaheswari, Appavoo |e verfasserin |4 aut | |
245 | 1 | 0 | |a Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma |
264 | 1 | |c 2019 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 28.02.2020 | ||
500 | |a Date Revised 28.02.2020 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
520 | |a BACKGROUND: The available treatment option for any type of cancer including CTCL is chemotherapy and radiation therapy which indiscriminately persuade on the normal cells. One way out for selective destruction of CTCL cells without damaging normal cells is the use of histone deacetylase inhibitors (HDACi). Despite promising results in the treatment of CTCL, these HDACi have shown a broadband inhibition profile, moderately selective for one HDAC class but not for a particular isotype. The prevalence of drug-induced side effects leaves open a narrow window of speculation that the decreased therapeutic efficacy and observed side effects may be most likely due to non specific HDAC isoform inhibition. The aim of this paper is to synthesis and evaluates HDAC8 isoform specific inhibitors | ||
520 | |a METHODS: Based on the preliminary report on the design and in silico studies of 52 hydroxamic acid derivatives bearing multi-substituent heteroaromatic rings with chiral amine linker, five compounds were shortlisted and synthesized by microwave assisted approach and high yielding synthetic protocol. A series of in vitro assays in addition to HDAC8 inhibitory activity was used to evaluate the synthesised compounds | ||
520 | |a RESULTS: Inhibitors 1e, 2e, 3e, 4e and 5e exerted the anti-proliferative activities against CTCL cell lines at 20- 100 µM concentrations. Both the pyrimidine- and pyridine-based probes exhibited μM inhibitory activity against HDAC8. The pyrimidine-based probe 1e displayed remarkable HDAC8 selectivity superior to that of the standard drug, SAHA with an IC50 at 0.1µM | ||
520 | |a CONCLUSION: Our study demonstrated that simple modifications at different portions of pharmacophore in the hydroxamic acid analogues are effective for improving both HDAC8 inhibitory activity and isoform selectivity. Potent and highly isoform-selective HDAC8 inhibitors were identified. These findings would be expedient for further development of HDAC8-selective inhibitors | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a HDAC8i | |
650 | 4 | |a chiral | |
650 | 4 | |a hydroxamates | |
650 | 4 | |a in vitro validation | |
650 | 4 | |a lymphoma | |
650 | 4 | |a microwave synthesis. | |
650 | 7 | |a Antineoplastic Agents |2 NLM | |
650 | 7 | |a Histone Deacetylase Inhibitors |2 NLM | |
650 | 7 | |a Hydroxamic Acids |2 NLM | |
650 | 7 | |a Isoenzymes |2 NLM | |
650 | 7 | |a Repressor Proteins |2 NLM | |
650 | 7 | |a HDAC8 protein, human |2 NLM | |
650 | 7 | |a EC 3.5.1.98 |2 NLM | |
650 | 7 | |a Histone Deacetylases |2 NLM | |
650 | 7 | |a EC 3.5.1.98 |2 NLM | |
700 | 1 | |a Puratchikody, Ayarivan |e verfasserin |4 aut | |
700 | 1 | |a Hari, Natarajan |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Anti-cancer agents in medicinal chemistry |d 2006 |g 19(2019), 7 vom: 29., Seite 916-934 |w (DE-627)NLM160693403 |x 1875-5992 |7 nnns |
773 | 1 | 8 | |g volume:19 |g year:2019 |g number:7 |g day:29 |g pages:916-934 |
856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871520619666190301150254 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 19 |j 2019 |e 7 |b 29 |h 916-934 |